共查询到20条相似文献,搜索用时 15 毫秒
1.
Bock O Hussein K Brakensiek K Buhr T Schlué J Wiese B Kreipe H 《Leukemia research》2007,31(6):799-803
The suppressor of cytokine signalling-1 (SOCS-1) is a negative regulator of signal transduction mediated by cytoplasmic tyrosine kinases such as the Janus kinases (JAKs). We investigated SOCS-1 expression in bone marrow cells from Philadelphia chromosome negative chronic myeloproliferative disorders (Ph(-) CMPD) and normal haematopoiesis (n=121), and additionally in peripheral blood samples (n=18). Except for chronic idiopathic myelofibrosis harbouring wild-type JAK2, other Ph(-) CMPD expressed significantly higher SOCS-1 levels of up to 14-fold compared to the control group (p<0.001) independent of the JAK2 status. The mononuclear cell fraction but not granulocytes in patients with Polycythaemia vera also significantly overexpressed SOCS-1. We conclude that up-regulation of the SOCS-1 gene might reflect a compensatory feedback mechanism with different emphasis among Ph(-) CMPD subtypes independent of an underlying JAK2 (V617F) mutation. 相似文献
2.
Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications 总被引:1,自引:0,他引:1
The chronic myeloproliferative disorders (CMPD) are a group of clinically related diseases characterized by clonal hematopoiesis with increased proliferation of one or more myeloid cell lineages. The identification of JAK2 mutations (JAK2V617F and JAK2 exon 12) in patients with CMPD is of great significance in the understanding of the molecular mechanisms underlined the pathogenesis of the disease contributing also to clinical management of patients. However, the precise pathogenetic contribution of JAK2 mutation is far from being fully elucidated and it is currently under intense investigation. Testing of JAK2 mutations has made the diagnosis of CMPD more precise than ever before, while genotype–phenotype associations have been identified. Furthermore, the discovery of JAK2 mutations facilitated the development of new targeted therapies and clinical trials are currently ongoing. 相似文献
3.
Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications 总被引:10,自引:0,他引:10
Panani AD 《Cancer letters》2007,255(1):12-25
Chronic myeloproliferative disorders (CMPD) are clonal disorders of the hematopoietic stem cell. The myeloid lineage shows increased proliferation with effective maturation, while peripheral leukocytosis, thrombocytosis or elevated red blood cell mass are found. In Philadelphia negative CMPD recurrent cytogenetic abnormalities occur, but no specific abnormality has been defined to date. The spectrum of cytogenetic aberrations is heterogeneous ranging from numerical gains and losses to structural changes including unbalanced translocations. The most common chromosomal abnormalities are 20q-, 13q-, 12p-, +8, +9, partial duplication of 1q, balanced translocations involving 8p11 and gains in 9p. Cytogenetic analysis of CMPD by conventional or molecular techniques has an important role in establishing the diagnosis of a malignant disease, adding also more information for disease outcome. Molecular studies may detect the possible role of candidate genes implicated in the neoplastic process, addressing new molecular target therapies. FIP1L1/PDGFRalpha rearrangements, as well as alterations of PDGFRbeta or FGFR1 gene have been found to be associated with specific types of CMPD. Recently, a novel somatic mutation, JAK2V617F, has been reported in most of the polycthemia vera (PV) patients, as well as in a lower percentage in essential thrombocythemia (ET) or idiopathic myelofibrosis (IMF) patients. This finding represents the most important advance in understanding of the molecular mechanisms underlined the pathogenesis of CMPD, contributing to the classification and management of patients. 相似文献
4.
应用IGF-1基因缺失小鼠研究IGF-1与乳腺肿瘤血管生成的关系 总被引:1,自引:0,他引:1
背景与目的:胰岛素样生长因子家族(insulin-like growth factors,IGFs)在肿瘤发生发展中所起的作用日益受到重视,但其作用机制尚不清楚.本实验通过在肝特异性胰岛素样生长因子1(insulin-like growth factor 1,IGF-1)基因缺失(LID)小鼠体内建立稳定的原发性乳腺癌模型,探讨血清中IGF-1水平与乳腺肿瘤血管生成可能存在的关系.方法:使用肝特异性IGF-1基因缺失小鼠及对照鼠,用化学致癌剂7,12-二甲基苯蒽[7,12-dimethybenz(a)anthracene,DMBA]诱导原发性乳腺肿瘤,使用人参皂甙Rg3进行干预治疗.比较各组肿瘤发生情况并通过免疫组化方法检测血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达及微血管密度(microvessel density,MVD).结果:未管饲Rg3的对照鼠、未管饲Rg3的LID鼠、管饲Rg3的对照鼠及管饲Rg3的LID鼠的乳腺癌发病率依次为66.67%、33.33%、36.00%及12.00%.肿瘤平均直径四组依次为(0.79±0.20)cm、(0.37±0.08)cm、(0.32±0.08)cm及(0.15±0.05)cm.VEGF表达检测:未管饲Rg3的对照鼠平均光密度为0.34±0.10,阳性百分率(positive rate,PR)为0.04±0.02,均为各组中最高(P<0.05);管饲Rg3的LID鼠平均光密度0.13±0.03,阳性百分率0.01±0.00,均为各组中最低(P<0.05).以上四组MVD依次为31.9±5.3、26.8±4.9、20.1±4.9、14.4±4.9(P<0.05).结论:IGF-1与乳腺肿瘤的发生发展相关,降低血清IGF-1可抑制肿瘤血管生成而对乳腺肿瘤有抑制作用,应用血管生长抑制剂人参皂甙Rg3可增强这一效应. 相似文献
5.
Emmanouil SpanoudakisIoanna Bazdiara Despoina PantelidouIoannis Kotsianidis Vasilios PapadopoulosDimitrios Margaritis George XanthopoulidisEleftherios Moustakidis Stamatia MantzouraniGeorge Bourikas Costas Tsatalas 《Leukemia research》2011,35(4):459-464
Telomere exhaustion and increased telomerase activity are associated with the acquisition of aggressive molecular events in a variety of haematological malignancies. In Philadelphia chromosome negative myeloproliferative neoplasms (PhnegMPN's), telomere dynamics during clonal evolution of these diseases have not yet been fully elucidated. Herein we demonstrated that telomere shortening is a global phenomenon in PhnegMPN's, irrespective of disease phenotype, treatment administration and JAK2V617F mutational status but the presence of additional cytogenetic abnormalities further affects them. Consistent with the above finding, TA was upregulated in CD34+ haemopoietic progenitors from almost all PhnegMPN subgroups compared to healthy donors. Moreover, TL below the cut-off value of 27% could predict disease progression in PhnegMPN patients (PFS at 5 years 39% vs 81%). Thus, TL emerges as a new prognostic marker in PhnegMPN, reflecting probably the genetic instability of highly proliferating MPN clones. 相似文献
6.
S. Karabulut D. Duranyıldız F. Tas U. Gezer F. Akyüz M. Serilmez E. Ozgür C. T. Yasasever S. Vatansever N. F. Aykan 《Tumour biology》2014,35(3):2729-2739
The principal aim of our study was to investigate the usefulness of serum protein and circulating mRNA of insulin-like growth factor-1 (IGF-1) as a diagnostic and prognostic tool in hepatocellular carcinoma (HCC). Fifty-four HCC patients and age- and sex-matched 20 healthy controls were enrolled into this study. Pretreatment serum IGF-1 and IGF-1 mRNA were determined by the solid-phase sandwich ELISA and quantitative RT-PCR method, respectively. The median age at diagnosis was 60 years, range 36–77 years; where majority of group were male (n?=?48, 88.8 %). All patients had cirrhotic history. Forty-six percent (n?=?25) of patients had Child-Pugh score A, 30 % (n?=?16) had score B or C. All of the patients were treated with local therapies and none of them received sorafenib. The baseline serum IGF-1 mRNA levels were significantly higher in HCC patients than in the control group (p?=?0.04), whereas no significant difference was observed for IGF-1 protein levels between the two group (p?=?0.18). Patients with history of HBV infection, who were not treated, and who received multiple palliative treatment for HCC had higher serum IGF-1 mRNA levels (p?=?0.03, 0.03, and 0.05, respectively). Poor performance status (p?<?0.001), viral etiology of cirrhosis (p?=?0.03), larger tumor size (p?=?0.01), lower serum hemoglobin levels (p?=?0.03), and not be treated for HCC (p?=?0.001) related to worse survival. However, neither serum IGF-1 nor serum IGF-1 mRNA had significantly adverse effect on survival (p?=?0.53 and 0.42, respectively). 相似文献
7.
8.
Faruk Tas Senem Karabulut Elif Bilgin Didem Tastekin Derya Duranyildiz 《Tumour biology》2014,35(9):9303-9309
Insulin-like growth factor-1 (IGF-1) and its primary binding protein-3 (IGFBP-3) play an important role in cellular proliferation, differentiation and apoptosis in many tumors, including breast cancer (BC). The objective of this study was to determine the clinical significance of the serum levels of IGF-1 and IGFBP-3 in BC patients. A total of 96 patients with a pathologically confirmed diagnosis of BC were enrolled into this study. Serum IGF-1 and IGFBP-3 levels were determined by the solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) methods. Age- and sex-matched 30 healthy controls were included in the analysis. The median age of diagnosis was 48 years (range: 29–80). Thirty-seven (39 %) consisted of metastatic disease. No significant difference in baseline serum was found in both IGF-1 and IGFBP-3 levels between BC patients and healthy controls (p?=?0.92 and p?=?0.26, respectively). None of the prognostic parameters analyzed was correlated significantly with the serum assay concentrations. Likewise, no correlations were also found between these serum concentrations and response to chemotherapy. No significant correlation was found between serum IGF-1 and IGFBP-3 levels in BC patients (r s?=?0.048, p?=?0.66).The patients with elevated serum IGF-1 levels had favorable in survival than those with lower levels (p?=?0.05). However, serum IGFBP-3 concentrations were found no prognostic role for outcome (p?=?0.35). In conclusion, elevated serum IGF-1 level is afavorable prognostic factor for overall survival in BC patients. 相似文献
9.
Perlino E Ciampolillo A Maenza S Marra E Derobertis O Ambrosi A Giorgino R Quagliariello E 《Oncology reports》1996,3(4):753-757
Thyroid cell growth and function both in vivo and in vitro, are mainly regulated by TSH. Recent studies have shown that growth factors including insulin-like growth factors (IGF-1) have an important role in the control of thyrocyte proliferation and differentiation. The aim of this study was to evaluate the expression of the IGF-1 gene by Northern analysis and the IGF-1 tissue protein by radioimmunoassay in multinodular euthyroid goiters. The study population consisted of 20 patients with multinodular goiter (14 females and 6 males) living in a non endemic geographic area. All patients were euthyroid at the time of surgery and submitted to total or subtotal thyroidectomy. Samples of normal thyroid tissue were obtained from three patients who were operated due to laryngeal carcinomas. The IGF-1 protein content was increased in non toxic multinodular goiter, 22 ng/g vs. 14 in controls (p<0.03), as was IGF-1 gene expression (p<0.05). The increase in the steady state mRNA content correlated with the increase in the protein content (r=0.665; p<0.005). These results suggest that IGF-1 may play a role in proliferation events involved in benign hyperplastic thyroid diseases. 相似文献
10.
11.
Overexpression of human IGF-1 with the bovine keratin 5 (BK5) promoter (BK5.IGF-1 transgenic mice) induces persistent epidermal hyperplasia and leads to spontaneous skin tumor formation. In previous work, PI3K and Akt activities were found to be elevated in the epidermis of BK5.IGF-1 transgenic mice compared to nontransgenic littermates. In the present study, we examined the importance of the PI3K/Akt signaling pathway in mediating the skin phenotype and the skin tumor promoting action of IGF-1 in these mice. Western blot analyses with epidermal lysates showed that signaling components downstream of PI3K/Akt were altered in epidermis of BK5.IGF-1 mice. Increased phosphorylation of GSK-3 (Ser(9/21)), TSC2(Thr(1462)), and mTOR(Ser(2448)) was observed. In addition, hypophosphorylation and increased protein levels of beta-catenin were observed in the epidermis of BK5.IGF-1 mice. These data suggested that components downstream of Akt might be affected, including cell cycle machinery in the epidermis of BK5.IGF-1 mice. Protein levels of cyclins (D1, E, A), E2F1, and E2F4 were all elevated in the epidermis of BK5.IGF-1 mice. Also, immunoprecipitation experiments demonstrated an increase in cdk4/cyclin D1 and cdk2/cyclin E complex formation, suggesting increased cdk activity in the epidermis of transgenic mice. In further studies, the PI3K inhibitor, LY294002, significantly blocked IGF-1-mediated epidermal proliferation and skin tumor promotion in DMBA-initiated BK5.IGF-1 mice. In addition, inhibition of PI3K/Akt with LY294002 reversed many of the cell cycle related changes observed in untreated transgenic animals. Collectively, the current results supported the hypothesis that elevated PI3K/Akt activity and subsequent activation of one or more downstream effector pathways contributed significantly to the tumor promoting action of IGF-1 in the epidermis of BK5.IGF-1 mice. 相似文献
12.
13.
14.
The antigenic phenotype of myelomonocytic progenitors [colony-forming unit granulocyte-macrophage (CFU-GM)] from 33 patients with chronic myeloproliferative disorders was investigated using four cytotoxic monoclonal antibodies. Monoclonal antibodies S3-13, S8-6, and S16-144 which recognize normal hemopoietic progenitors of different lineages reacted with almost all CFU-GM. R1B-19 monoclonal antibody identified two subpopulations of myelomonocytic progenitors (type 1 and 2 CFU-GM), as reported previously in normal subjects. In 3 of 11 patients with chronic myelogenous leukemia, in 1 of 2 patients with chronic myelomonocytic leukemia, and in 2 of 4 patients with polycythemia vera, a higher proportion of the more immature CFU-GM (type 1) was detected in bone marrow cells. The more differentiated CFU-GM (type 2) is not detectable in normal peripheral blood. By contrast, in 14 of 15 chronic myelogenous leukemia patients, in 1 of 2 chronic myelomonocytic leukemia patients and in 3 of 8 patients with idiopathic myelofibrosis, it was present in high to very high proportions. It is clear from these findings that the antigens present on normal CFU-GM are expressed in chronic myeloproliferative disorders. The proportion and distribution of type 1 and 2 CFU-GM, on the other hand, are very different from those observed in the normal subjects. 相似文献
15.
Abnormalities of chromosome 1 in myeloproliferative disorders. 总被引:1,自引:0,他引:1
J D Rowley 《Cancer》1975,36(5):1748-1757
Three patients with myeloproliferative disorders showed a similar chromosome abnormality, accompanied by other abnormalities that were different in each case. Marrow cells from all three patients were trisomic either for the entire chromosome 1 or for its long arm. Patient 1 had a brief period of anemia and thrombocytopenia which preceded a terminal acute leukemia; Patient 2 had polycythemia vera (P.V.) that terminated in acute leukemia; and Patient 3 has P.V. The detection of an abnormal karyotype in Patients 1 and 2 was an important factor in establishing the diagnosis of acute leukemia. Preliminary evidence supports the suggestion that some chromosomal changes are nonrandom in myeloproliferative diseases. Nonrandom abnormalities involving the same chromosome have been observed in several human neoplastic disorders. 相似文献
16.
Faruk Tas Senem Karabulut Murat Serilmez Rumeysa Ciftci Derya Duranyildiz 《Tumour biology》2014,35(4):3125-3132
Insulin-like growth factor-1 (IGF-1) and its primary binding protein IGFBP-3 play an important role in cellular proliferation, differentiation, and apoptosis in many tumors, including ovarian cancer. The objective of this study was to determine the clinical significance of the serum levels of IGF-1 and IGFBP-3 in epithelial ovarian cancer (EOC) patients. A total of 50 patients with a pathologically confirmed diagnosis of EOC were enrolled into this study. Serum IGF-1 and IGFBP-3 levels were determined by the solid-phase sandwich ELISA method. Twenty age- and sex-matched healthy controls were included in the analysis. Median age of patients was 56.5 years old (range 22 to 83 years). Majority of the patients had advanced disease (FIGO stage III–IV; 90 %). No significant difference was observed in baseline serum IGF-1 and IGFBP-3 levels between EOC patients and healthy controls (p?=?0.99 and p?=?0.80, respectively). The young patients had higher serum IGF-1 and IGFBP-3 concentrations (p?=?0.04 and p?=?0.02, respectively). Patients with normal CA-125 levels had higher serum IGFBP-3 concentrations compared with those with higher CA-125 levels (p?=?0.008). However, no other clinical variables including histology, tumor grade, stage of disease, and response to chemotherapy were found to be correlated with serum IGF assays (p?>?0.05). A trend to significant relationship was found between the serum levels of IGF-1 and IGFBP-3 (r s?=?0.212, p?=?0.07). The patients with elevated serum IGF-1 levels had favorable progression-free and overall survivals than those with lower levels (p?=?0.04 and p?=?0.03, respectively). However, serum IGFBP-3 concentrations were found to have no prognostic role for both survivals (p?=?0.12 and p?=?0.26, respectively). In conclusion, elevated serum level of IGF-1 is associated with favorable progression-free and overall survivals in EOC patients. 相似文献
17.
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD) 总被引:1,自引:0,他引:1
Wróbel T Mazur G Surowiak P Wolowiec D Jelen M Kuliczkowsky K 《Pathology oncology research : POR》2003,9(3):170-173
Angiogenesis is a multistep process of the development of capillaries from established blood vessels. Angiogenesis probably plays a significant role in the development and progression of hematopoietic malignancies. Higher microvascular density and increased serum levels of proangiogenic factors such as vascular endothelial growth factor (VEGF) or basic fibroblasts growth factor (bFGF) have been reported in acute and chronic leukemias, myeloproliferative and myelodysplastic disorders, multiple myeloma and lymphomas. The microvessel density of bone marrow stroma in myeloproliferative disorders is increased and VEGF is considered as the most potent endothelial cell activator. The purpose of this study was to examine the expression of VEGF in bone marrow of patients with MPD. 60 paraffinembedded bone marrow core biopsy specimens from newly diagnosed patients with MPD were evaluated. In addition 10 bone marrow core biopsy specimens from adult patients without evidence of malignancy were used as controls. Bone marrow sections were stained immunohistochemically for VEGF (PharMingen, USA). Obtained data show that MPD are associated with an increased expression of VEGF in the bone marrow. This observation support previous studies suggesting that angiogenesis may play a role in the pathophysiology of myeloproliferative disorders. Clinical significance of this phenomenon needs further investigation however thus provides rationale for use of angiogenesis inhibitors in MPD therapy. 相似文献
18.
Elevated insulin-like growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion 总被引:2,自引:0,他引:2
Olchovsky D Shimon I Goldberg I Shulimzon T Lubetsky A Yellin A Pariente C Karasik A Kanety H 《Acta oncologica (Stockholm, Sweden)》2002,41(2):182-187
Insulin-like growth factor-1 (IGF-1) and its binding proteins (IGFBPs) are produced by many tissues and are present in serum and other biological fluids. Alterations in sera of IGF-1 and 2 and IGFBPs were demonstrated in patients with malignancy, infection and other diseases causing pleural effusion. In this study the IGF-1 and IGFBP-2 content and the specific electrophoretic patterns of IGFBPs in samples of sera and pleural effusions of 25 patients with malignancy, infection and congestive heart failure were investigated. IGF-1 levels in exudative effusions of malignant solid tumors were significantly higher [(mean +/- SD), 20.9+/-7.5 nmol/L, n = 9] than in lymphoma (11.0+/-5.2 nmol/L, n = 5; p < 0.05), infection (11.4+/-6.5 nmol/L, n = 6; p < 0.05) and transudative effusion of congestive heart failure (4.3+/-3.3 nmol/L, n = 5; p < 0.02). IGFBP-2 was markedly increased in effusions of malignant solid tumors (2.14+/-0.82 mg/L, n = 9) compared with exudates of lymphoma, infection and transudates (1.10+/-0.70, 1.22+/-0.32 and 0.93+/-0.52 nmol/L, respectively, p < 0.05). Moreover, in effusion of solid tumors, IGFBP-2 levels were higher than those in corresponding sera, which suggests local production of this binding protein. The demonstration of IGFBP-2 in solid tumor cells by immunohistochemistry further supports this possibility. This work demonstrates the existence of the IGF-1/IGFBP system in pleural fluids from different etiologies and implies possible use of IGF-1 and IGFBP-2 as a potential marker of malignant effusions. 相似文献
19.
Characteristics and outcome of patients with Philadelphia chromosome negative,bcr/abl negative chronic myelogenous leukemia 总被引:2,自引:0,他引:2
Onida F Ball G Kantarjian HM Smith TL Glassman A Albitar M Scappini B Rios MB Keating MJ Beran M 《Cancer》2002,95(8):1673-1684
BACKGROUND: Up to 5% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia (Ph) translocation t(9;22)(q34;q11) or a bcr/abl molecular rearrangement. Although the diagnostic criteria of this entity are still under debate, there is general agreement that patients with Ph negative, bcr/abl negative CML have a severe clinical course that is not affected significantly by current treatment options. METHODS: A population of 76 patients with bcr/abl negative CML who had received minimal or no previous therapy was characterized carefully with the intent of investigating clinical and hematologic variables and their association with survival by univariate, correlation, and multivariate analyses. A group of 73 patients with Ph negative CML who were not tested for the bcr/abl rearrangement (bcr/abl unknown) was analyzed separately and used for extension of the analysis. RESULTS: In the bcr/abl negative patient population, the median overall survival was 24 months. At the time of the analysis, 38 patients (50%) had died, and blastic transformation preceded death in 31%. Chromosomal abnormalities were found in 30% of the 76 patients, with trisomy 8 the most common abnormality. Complex chromosomal abnormalities were rare, and monosomy 7 was not observed. Survival was not affected significantly by treatment. Multivariate analysis identified older age (> 65 years), anemia (hemoglobin < 10 g/dL), and severe leukocytosis (white blood cells > 50 x 10(9)/L) as variables with independent prognostic significance for poor survival. A prognostic scoring system stratified patients into a low-risk group (53%) and a high-risk group (47%), with median survivals of 38 months and 9 months, respectively. CONCLUSIONS: Bcr/abl negative CML is a distinct clinical entity associated with very poor prognosis. Two risk categories are identifiable using a simple scoring system based on age, hemoglobin level, and leukocyte number. 相似文献